Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 181Breast Neoplasms 154Prostatic Neoplasms 144Lung Neoplasms 139Glioblastoma 119Head and Neck Neoplasms 115Squamous Cell Carcinoma of Head and Neck 110Rectal Neoplasms 107Lymphoma 101Esophageal Neoplasms 100Pancreatic Neoplasms 76Esophageal Squamous Cell Carcinoma 71Leukemia 70Neoplasms 67Brain Neoplasms 67Lymphoma, Follicular 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Non-Hodgkin 62Lymphoma, Large B-Cell, Diffuse 58Hodgkin Disease 56Uterine Cervical Neoplasms 53Central Nervous System Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Gliosarcoma 51Sarcoma 50Colorectal Neoplasms 50Neoplasm Metastasis 45Lymphoma, Large-Cell, Immunoblastic 45Glioma 44Burkitt Lymphoma 43

Interventions

dehydroftorafur 2Taxes 2Radiotherapy 2Radiation 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Capecitabine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Adenocarcinoma × Radiotherapy × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT02394535 2022-09-02

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
25 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡